None listed
Conditions
Brief summary
Pleural effusion is a build-up of fluid in the pleural space, the thin space between the lungs and the inner surface of the chest wall. Normally, there is a small amount of fluid in this space. However, due to many different reasons, the fluid in the pleural space can accumulate. Among these causes are pleural infectious effusions, specifically (simple and complicated) parapneumonic effusion and empyema. Parapneumonic effusions and empyema are increasing in incidence and associated with high morbidity and mortality. Empyema carries a case-fatality ratio of up to 20% overall and up to 42% in patients with significant comorbidities, such as lung cancer. This prospective cohort study aims to assess the current aetiology, patients’ characteristics, new biomarkers, clinical outcomes, and quality of life in patients with parapneumonic effusion or empyema. To be able to better understand the opportunities for improving diagnostics and outcomes in future patients with empyema and parapneumonic pleural effusion. In addition, we aim to establish a biobank for future unspecified research of participant data and samples enrolled in the PEACE study.
Interventions
This single centre prospective cohort study aims to assess the current aetiology, patients’ characteristics, complications, (new) biomarkers, clinical outcome, and quality of life in patients with parapneumonic effusion or empyema.
All adult patients admitted to the respiratory medicine ward at Christchurch Hospital with empyema or parapneumonic effusion and who meet all inclusion and no exclusion criteria will be invited to participate. Participants will be recruited between August 2021 and Au
This single centre prospective cohort study aims to assess the current aetiology, patients’ characteristics, complications, (new) biomarkers, clinical outcome, and quality of life in patients with parapneumonic effusion or empyema. All adult patients admitted to the respiratory medicine ward at Christchurch Hospital with empyema or parapneumonic effusion and who meet all inclusion and no exclusion criteria will be invited to participate. Participants will be recruited between August 2021 and August 2023, with a longitudinal follow-up for 1 year. The majority of data will be obtained through standard care, using the Canterbury Hospital HealthPathway of ‘Pleural Effusion’. Data will be collected from the patient’s electronic hospital file and the patient during admission, with the use of a patient questionnaire. During the study, we will take additional blood and pleural fluid samples. Samples will be taken only once, at baseline, during hospital admission. The quality of life and symptom measurements are additional as well to the standard care. The patient will be asked to complete questionnaires on quality of life and symptoms on admission, at discharge, and during follow-up after discharge (1, 6, and 12 months). During follow-up, based on individual preferences, the participant will be sent the questionnaires by mail with a return envelope or by email via Qualtrics.
Sponsors
University of Otago, Christchurch
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Age > 18 years - Clinical suspicion of parapneumonic effusion (simple and complicated) or empyema. - Clinically indication pleural aspiration or drainage
Exclusion criteria
- Earlier enrolment to the study - Not able to provide informed consent - Treatment failure or complication from recent medical intervention (e.g. pleural drainage, VATS)
Outcome results
None listed